WT-2108

WT-2108 is a small molecule antagonist of the Transient Receptor Potential Vanilloid (TRPV) channel family, currently under development by Hangzhou Westan Pharmaceutical Technology. The compound is primarily being advanced for the treatment of pruritus (chronic itch), for which an Investigational New Drug (IND) application has been filed. Additionally, WT-2108 is being explored in preclinical studies for its potential in managing respiratory allergic diseases such as asthma and allergic rhinitis. The mechanism involves blocking TRPV-mediated sensory signaling and inflammatory pathways, which are key drivers in the pathogenesis of chronic itch and airway hypersensitivity. By inhibiting these channels, WT-2108 aims to modulate sensory nerve activation and reduce the associated inflammatory response.